Cutting-Edge Medical Devices by Biot Korea

Biot Korea, founded in 2017 by CEO Jang Young-jun, aims to boost treatment outcomes with groundbreaking medical devices. Focused on innovation, the company’s products are designed to improve the effectiveness of disease treatments through collaboration and research.

Biot Korea’s Innovations

Biot Korea, located within the Gwangju R&D Special Zone, specializes in creating “First in Class” medical devices.

Key Products

1. Magnectio

   • Delivers micro-sized structures for targeted therapy.
   • Uses electromagnetic external drive devices for precise delivery.
   • Promotes maximum treatment effectiveness in disease management.
   • Consists of:
     • MagLus: Medical-grade biocompatible material loaded with drugs or stem cells.
     • EMA: Generates and controls electromagnetic fields for accurate device operation.
     • Wearable Device: Stabilizes MagLus during treatment.

2. HyuFIL

   • Designed for arthroscopic procedures in knees and shoulders.
   • Cleans surgical saline residue.
   • Temporarily enhances joint lubrication to reduce mechanical friction.
   • Biocompatible with properties mimicking natural joint fluid.

Clinical Trials and Market Strategy

• Magnectio is a Class 4 medical device set for clinical trials in 2026.
• Split strategy for quicker revenue includes:
  • Initial release as a veterinary device.
  • Human clinical validation follows.
• HyuFIL has completed regulatory and insurance registrations.
  • Aiming for extensive market adoption with active sales discussions.
  • 2025 target: 5,000 units sold.

Investment and Business Expansion

Biot Korea continues to attract substantial investments across different rounds:

• 2018: Seed investment from Enlight Ventures.
• 2021: Series A led by Korea Investment Partners, securing 4 billion KRW.
• Ongoing: Series B targeting 6 billion KRW with a 30 billion KRW company valuation.
• Engaging existing and new venture capital networks for 2025 funding projection.

Leadership and Vision

Jang Young-jun’s background in marketing and manufacturing investment at Hyundai provides a strong foundation for Biot Korea’s trajectory. His aim is to leverage this experience in a field safeguarded by patents and regulatory protocols.

Achievements

• Registered 28 patents globally (19 domestic, 9 international).
• Multiple industry awards, including Ministerial Commendations.
• Certifications in GMP, CE, and export manufacturing underline product credibility.

Future Prospects

Biot Korea aims to revolutionize medical treatment standards through collaborative efforts and cutting-edge technology. By focusing on significant R&D projects, the company seeks continual development and sustainable market presence.

Delivering hope to chronic disease patients and contributing to society remains a core mission for Biot Korea. This enhances both health outcomes and economic influence within the medical device industry.

Table of Contents:

1. Introduction
   • Overview of Biot Korea’s mission and vision
   • Significance of innovation in medical devices for improved treatment outcomes
2. Biot Korea’s Innovations
   • Location and focus within the Gwangju R&D Special Zone
   • Overview of “First in Class” medical devices developed by the company
3. Key Products
   • Magnectio:
     • Description and function as a targeted therapy device
     • Components of Magnectio:
       • MagLus: Medical-grade biocompatible material for drug/stem cell delivery
       • EMA: Electromagnetic field generation for device operation
       • Wearable Device: Stabilizes MagLus during treatment
   • HyuFIL:
     • Purpose and design for arthroscopic procedures
     • Mechanism for cleaning surgical saline residue and enhancing joint lubrication
4. Clinical Trials and Market Strategy
   • Overview of the regulatory status of Magnectio (Class 4) and plans for veterinary and human clinical trials
   • Market strategy for HyuFIL, including regulatory and insurance registrations
   • Sales goals for 2025 targeting 5,000 units
5. Investment and Business Expansion
   • Summary of funding rounds and investments secured by Biot Korea
   • Impact of financial backing on growth and development initiatives
6. Leadership and Vision
   • Background of CEO Jang Young-jun and his expertise in marketing and manufacturing
   • Strategic approach to leveraging experience in the medical device sector
7. Achievements
   • Overview of registered patents and industry recognition
   • Importance of certifications in GMP, CE, and export manufacturing
8. Future Prospects
   • Vision for revolutionizing medical treatment standards
   • Commitment to R&D and sustainable market presence
   • Role in improving health outcomes for chronic disease patients
9. Conclusion
   • Recap of Biot Korea’s contributions to the medical device industry
   • Encouragement to follow the company’s innovations and their impact on healthcare